+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Diabetes Associated Ophthalmic Treatment Market by Product Type (Devices, Drugs), Application (Cataract, Diabetic associated Macular Degeneration, Diabetic Macular Edema), End-use - Forecast 2024-2030- Product Image
Global Diabetes Associated Ophthalmic Treatment Market by Product Type (Devices, Drugs), Application (Cataract, Diabetic associated Macular Degeneration, Diabetic Macular Edema), End-use - Forecast 2024-2030- Product Image
Sale

Global Diabetes Associated Ophthalmic Treatment Market by Product Type (Devices, Drugs), Application (Cataract, Diabetic associated Macular Degeneration, Diabetic Macular Edema), End-use - Forecast 2024-2030

  • PDF Icon

    Report

  • 181 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5716081
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diabetes Associated Ophthalmic Treatment Market size was estimated at USD 5.71 billion in 2023, USD 6.18 billion in 2024, and is expected to grow at a CAGR of 8.59% to reach USD 10.18 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Diabetes Associated Ophthalmic Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetes Associated Ophthalmic Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Diabetes Associated Ophthalmic Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., Alimera Sciences, Inc., Allergan PLC, Ampio Pharmaceuticals, Inc., Apexian Pharmaceuticals, Inc., Bausch & Lomb Incorporated., Bayer AG, Eisai Co Ltd., Graybug Vision Inc., Kalvista Pharmaceuticals Ltd., Kodiak Sciences Inc., Kubota Vision Inc., Novartis AG, Ocuphire Pharma, Inc., and Regeneron Pharmaceuticals Inc.

Market Segmentation & Coverage

This research report categorizes the Diabetes Associated Ophthalmic Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product Type
    • Devices
    • Drugs
  • Application
    • Cataract
    • Diabetic associated Macular Degeneration
    • Diabetic Macular Edema
    • Diabetic Retinopathy
    • Dry Eye Syndrome
    • Eye Allergy & Infection
    • Glaucoma
    • Uveitis
  • End-use
    • Ambulatory Surgical Centers
    • Hospitals
    • Ophthalmic Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Diabetes Associated Ophthalmic Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetes Associated Ophthalmic Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Diabetes Associated Ophthalmic Treatment Market?
  4. What is the market share of the leading vendors in the Diabetes Associated Ophthalmic Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Diabetes Associated Ophthalmic Treatment Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Diabetes Associated Ophthalmic Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of diabetes with rising geriatric population
5.1.1.2. Growing inclination towards early diagnosis of diabetes
5.1.1.3. Rising number of initiatives to increase awareness associated diabetes ophthalmic disease
5.1.2. Restraints
5.1.2.1. Lack of skilled and knowledgeable ophthalmologists
5.1.3. Opportunities
5.1.3.1. Rising R&D activities to develop advanced diabetes associated ophthalmic treatments
5.1.3.2. High potential for diabetes associated ophthalmic treatment devices
5.1.4. Challenges
5.1.4.1. Long duration of drug approvals for diabetes associated ophthalmic treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Diabetes Associated Ophthalmic Treatment Market, by Product Type
6.1. Introduction
6.2. Devices
6.3. Drugs
7. Diabetes Associated Ophthalmic Treatment Market, by Application
7.1. Introduction
7.2. Cataract
7.3. Diabetic associated Macular Degeneration
7.4. Diabetic Macular Edema
7.5. Diabetic Retinopathy
7.6. Dry Eye Syndrome
7.7. Eye Allergy & Infection
7.8. Glaucoma
7.9. Uveitis
8. Diabetes Associated Ophthalmic Treatment Market, by End-use
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Ophthalmic Centers
9. Americas Diabetes Associated Ophthalmic Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Diabetes Associated Ophthalmic Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Diabetes Associated Ophthalmic Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Adverum Biotechnologies, Inc.
13.1.2. Alimera Sciences, Inc.
13.1.3. Allergan PLC
13.1.4. Ampio Pharmaceuticals, Inc.
13.1.5. Apexian Pharmaceuticals, Inc.
13.1.6. Bausch & Lomb Incorporated.
13.1.7. Bayer AG
13.1.8. Eisai Co Ltd.
13.1.9. Graybug Vision Inc.
13.1.10. Kalvista Pharmaceuticals Ltd.
13.1.11. Kodiak Sciences Inc.
13.1.12. Kubota Vision Inc.
13.1.13. Novartis AG
13.1.14. Ocuphire Pharma, Inc.
13.1.15. Regeneron Pharmaceuticals Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET DYNAMICS
FIGURE 7. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 8. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 12. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 6. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 9. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CATARACT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC ASSOCIATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE ALLERGY & INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 18. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 31. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 32. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 34. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 48. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 51. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 57. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 75. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 88. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 91. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 94. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 97. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 103. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 104. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 112. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 115. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 116. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 118. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 130. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 139. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 148. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 149. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 150. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET LICENSE & PRICING

Companies Mentioned

  • Adverum Biotechnologies, Inc.
  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • Apexian Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated.
  • Bayer AG
  • Eisai Co Ltd.
  • Graybug Vision Inc.
  • Kalvista Pharmaceuticals Ltd.
  • Kodiak Sciences Inc.
  • Kubota Vision Inc.
  • Novartis AG
  • Ocuphire Pharma, Inc.
  • Regeneron Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.18 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.18 Billion
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Single Use Ophthalmic Surgical Devices Market by Product (Cannulas, Curettes, Forceps), Application (Cataract Surgery, Corneal Surgery, Diabetic Retinopathy), End-User - Forecast 2024-2030 - Product Image

Global Single Use Ophthalmic Surgical Devices Market by Product (Cannulas, Curettes, Forceps), Application (Cataract Surgery, Corneal Surgery, Diabetic Retinopathy), End-User - Forecast 2024-2030

  • Report
  • 189 Pages
  • Global
From
Macular Edema and Macular Degeneration Global Market Report 2024 - Product Image

Macular Edema and Macular Degeneration Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Global Ophthalmic Devices Market Size, Share & Trends Analysis Report by Product (OCT, Ophthalmic Ultrasound Imaging Systems), Application (Cataract, Glaucoma), End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Ophthalmic Devices Market Size, Share & Trends Analysis Report by Product (OCT, Ophthalmic Ultrasound Imaging Systems), Application (Cataract, Glaucoma), End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 140 Pages
  • Global
From
Global Ophthalmic Viscosurgical Devices Market by Product (Cohesive, Combined, Dispersive), Application (Cataract Surgery, Glaucoma Surgery, Keratoplasty), End User - Forecast 2023-2030 - Product Image

Global Ophthalmic Viscosurgical Devices Market by Product (Cohesive, Combined, Dispersive), Application (Cataract Surgery, Glaucoma Surgery, Keratoplasty), End User - Forecast 2023-2030

  • Report
  • 180 Pages
  • Global
From
Global Optometry Equipment Market by Type (OCT, Ophthalmoscope, Autorefractor, Tonometer, Slitlamp, Wavefront Analyzer), Application (General Examination, Cataract, Glaucoma), End User (Eye Clinics, Hospitals), and Region - Forecast to 2029 - Product Image

Global Optometry Equipment Market by Type (OCT, Ophthalmoscope, Autorefractor, Tonometer, Slitlamp, Wavefront Analyzer), Application (General Examination, Cataract, Glaucoma), End User (Eye Clinics, Hospitals), and Region - Forecast to 2029

  • Report
  • 278 Pages
  • Global
From

About the Diabetes Associated Ophthalmic Treatment Market

The Diabetes Associated Ophthalmic Treatment market encompasses a range of medical procedures, devices, and medications utilized in the management and care of eye conditions associated with diabetes, specifically diabetic retinopathy and diabetic macular edema. Diabetic retinopathy involves changes to retinal blood vessels that can cause them to bleed or leak fluid, distorting vision. Treatments for these conditions range from laser surgery to control bleeding to the administration of anti-VEGF drugs, which help to reduce abnormal blood vessel growth and swelling. Intravitreal injections of steroids can also be utilized for their anti-inflammatory effects. Additionally, there is a growing interest in the development and use of novel drug delivery systems and surgical instruments to improve the precision and efficacy of treatments. Furthermore, technological advancements in optical coherence tomography (OCT) aids in the early detection and management of diabetic eye diseases by providing high-resolution images of the retina. Regular screening among diabetic patients is crucial for early intervention and has become an integral part of diabetes care, helping to prevent vision loss. Several companies have established positions in the market, which include Novartis, Roche, Regeneron Pharmaceuticals, Bayer, and Abbott. These companies are involved in the production of therapeutics like anti-VEGF injections, as well as manufacturing devices and supplies for laser treatments and surgeries tailored to mitigate the ocular complications that arise from diabetes. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.